Stockreport

Cardiff Oncology Reports First Quarter 2024 Results and Provides Business Update [Yahoo! Finance]

Cardiff Oncology, Inc.  (CRDF) 
PDF - In RAS wild-type mCRC, preclinical data presented at AACR demonstrated onvansertib's antitumor activity both as a single agent and in combination, highlighting its br [Read more]